gip and glp-1 receptor agonist Mechanisms of action therapeutic applications of and dual GIP/GLP-1 agonists Alimentary Pharmacology & Therapeutics |

In patients with T2DM who are poorly controlled by metformin, increasing DUL from 1.5mg to 3.0mg or 4.5mg can provide glycosylated hemoglobin and weight loss related to clinically relevant doses and has similar safety (111)

Many also find it useful to develop certain eating habits, such as not eating when full and eating smaller meals more frequently

Needle gauge requirements vary by product but are not believed to be the main factor affecting patient preference (39)

By functioning as a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, Zepbound targets specific areas of the brain that control hunger and satiety

In this metabolic state, the body shifts from glucose to fat-derived ketone bodies as its primary fuel source

Moreover, while GLP-1 therapies help manage symptoms and risks, they do not cure diabetes or obesity